Quality of life and symptom distress after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Table 1 Patients’ characteristics and hyperthermic intraperitoneal chemotherapy parameters, n = 58

Variable	Number	Percentage
Sex
Male	19	32.8
Female	39	67.2
Age at CRS + HIPEC, years (median, range)	60 (22-78)
BMI, kg/m2 (mean, SD)	24.3 (4.5)
ECOG
0-1	55	94.8
2	3	5.2
Comorbidity
Hypertension	17	29.3
Diabetes mellitus	11	19
Hepatitis B	5	8.6
Hepatitis C	6	10.3
Primary or recurrent tumor
Primary	41	70.7
Recurrent	17	29.3
Primary cancer
Colorectal	9	15.5
Ovarian	15	25.9
Gastric	27	46.6
Others	7	12.1
Previous definitive surgery
No	35	60.3
Yes	23	39.7
Previous systemic chemotherapy
Never	22	37.9
1st line	23	39.7
2nd lines or more	13	22.4
PCI (median, range)	5.5 (0-39)
Completeness of cytoreduction score
0	46	79.3
1	8	13.8
2	1	1.7
3	3	5.2
Duration of peritonectomy, mins (median, range)	240 (0-610)
Length of hospital stay, days (median, range)	13 (7-39)
Surgical method
Laparotomy	53	91.4
Laparoscopy	5	8.6
HIPEC regimen
Cisplatin	43	74.1
Non-cisplatin	15	25.9
HIPEC indication
Adjuvant	16	27.6
Curative	39	67.2
Palliation	3	5.2
Duration of HIPEC, mins
60	46	75.9
90	12	20.7
Post-op complications
No	6	10.3
Yes	52	89.7
Post-op complications
Grade I	42	72.4
Grade II	6	10.3
Grade III	3	5.2
Grade IV	1	1.7
Nutrition (PGSGA score)
A	42	85.7
B	7	14.3

BMI: Body mass index; ECOG: Eastern cooperative oncology group performance

status; PCI: Peritoneal carcinomatosis index; PGSGA: Patient-generated subjective global assessment.